INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026
InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to trigger buying interest, especially from investors focused on government‑payor healthcare models.
Market read
First‑report earnings and guidance for a mid‑cap healthcare firm; material new data for traders.
What to watch
Potential risks from Medicaid reimbursement changes or higher debt servicing costs not fully disclosed.
InnovAge reported fiscal first-quarter 2027 total revenues of $264,757 (in thousands), net income of $20,878 (in thousands), and Adjusted EBITDA of $31,251 (in thousands), while confirming fiscal year 2027 guidance.
Revenue increased approximately 12.1%, income before income taxes increased approximately 153.1%, Center-level Contribution Margin increased 23.8%, and Adjusted EBITDA increased by $13.6 million. Margins expanded across income before income taxes, net income, Center-level Contribution Margin, and Adjusted EBITDA.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $264.8M | – | approximately 12.1% |
| Capitation revenue, three months ended September 30, 2026GAAP | $264.7M | – | – |
| Other service revenue, three months ended September 30, 2026GAAP | $67K | – | – |
| External provider costs, three months ended September 30, 2026GAAP | $115.7M | – | – |
| Cost of care, excluding depreciation and amortization, three months ended September 30, 2026GAAP | $85.50M | – | – |
| Sales and marketing expense, three months ended September 30, 2026GAAP | $8.63M | – | – |
| Corporate, general and administrative expense, three months ended September 30, 2026GAAP | $29.15M | – | – |
| Depreciation and amortization, three months ended September 30, 2026GAAP | $5.66M | – | – |
| Total expenses, three months ended September 30, 2026GAAP | $244.6M | – | – |
| Operating Income, three months ended September 30, 2026GAAP | $20.15M | – | – |
| Interest expense, net, three months ended September 30, 2026GAAP | −$123K | – | – |
| Other income, net, three months ended September 30, 2026GAAP | $10K | – | – |
| Income Before Income Taxes, three months ended September 30, 2026GAAP | $20.04M | – | approximately 153.1% |
| Income Before Income Taxes as a percent of revenue, three months ended September 30, 2026GAAP | 7.6% | – | an increase of 4.2 percentage points |
| Provision (Benefit) for Income Taxes, three months ended September 30, 2026GAAP | −$841K | – | – |
| Net Income, three months ended September 30, 2026GAAP | $20.88M | – | – |
| Net Income margin, three months ended September 30, 2026GAAP | 7.9% | – | an increase of 4.6 percentage points |
| Net Income Attributable to InnovAge Holding Corp., three months ended September 30, 2026GAAP | $19.55M | – | – |
| Net loss per share - basic, three months ended September 30, 2026GAAP | $0.14 | – | – |
| Net loss per share - diluted, three months ended September 30, 2026GAAP | $0.14 | – | – |
| Center-level Contribution Margin, three months ended September 30, 2026non-GAAP | $63.59M | – | 23.8% |
| Center-level Contribution Margin as a % of revenue, three months ended September 30, 2026non-GAAP | 24.0% | – | an increase of 2.2 percentage points |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | $31.25M | – | an increase of $13.6 million |
| Adjusted EBITDA margin, three months ended September 30, 2026non-GAAP | 11.8% | – | an increase of 4.3 percentage points |
| Census, fiscal first quarter 2027other | approximately 8,420 participants | – | – |
| Member months, fiscal first quarter 2027other | approximately 25,070 | – | – |
| Net cash provided by operating activities, three months ended September 30, 2026GAAP | $28.74M | – | – |
| Net cash used in investing activities, three months ended September 30, 2026GAAP | −$3.42M | – | – |
| Purchases of property and equipment, three months ended September 30, 2026GAAP | −$2.99M | – | – |
| Net cash used in financing activities, three months ended September 30, 2026GAAP | −$3.96M | – | – |
| Cash and cash equivalents as of September 30, 2026GAAP | $119.3M | – | – |
| Short-term investments as of September 30, 2026GAAP | $43.74M | – | – |
| Debt on the balance sheet at the end of fiscal first quarter 2027GAAP | $61.4M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| PACEPACE capitation revenue was $264,690 (in thousands). | $264.8M | – | – |
| All otherThe prior-year all other revenue was $257 (in thousands), primarily attributable to the Senior Housing operating segment, whose assets were sold on September 11, 2025. | $— (in thousands) | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Fiscal year 2027 outlook
- Revenue$1,050 to $1,085 (dollars in millions)
- NoteCensus: 8,625 to 8,850
- NoteTotal Member Months: 101,000 to 102,500
- NoteAdjusted EBITDA: $105 to $115 (dollars in millions, non-GAAP)
What drove it
- Continued census growth and disciplined clinical and operational execution were cited as drivers of financial performance.
- Census was approximately 8,420 participants, compared with 7,890 participants in the first quarter of fiscal year 2026.
- Member months were approximately 25,070, compared with 23,500 in the first quarter of fiscal year 2026.
- Center-level Contribution Margin increased 23.8% to $63,587 (in thousands), and its margin increased 2.2 percentage points to 24.0%.
- Corporate, general and administrative expense was $29,149 (in thousands), compared with $30,273 (in thousands).
- Interest expense, net was $(123) (in thousands), compared with $(1,251) (in thousands).
Concerns
- The Company stated that expected results and estimates may be impacted by factors outside its control and actual results may be materially different from guidance.
- Business optimization expense was $1,707 (in thousands), including $1.5 million related to organizational restructure and executive severance and $0.2 million related to closure of the previously planned de novo center in Downey, California.
- Offering expenses were $1,679 (in thousands) related to filing and legal fees for the Form S-3 Shelf Registration Statement and subsequent secondary offering.
- The forward-looking statement disclosures identify risks including reductions in PACE reimbursement rates, Medicaid budget reductions, healthcare cost inflation, labor shortages, and government-program reviews, audits and investigations.
What to watch
- Progress toward fiscal year 2027 census guidance of 8,625 to 8,850 and Total Member Months guidance of 101,000 to 102,500.
- Execution against fiscal year 2027 total revenues guidance of $1,050 to $1,085 and Adjusted EBITDA guidance of $105 to $115.
- Whether Center-level Contribution Margin and Adjusted EBITDA margins sustain the fiscal first-quarter levels of 24.0% and 11.8%, respectively.
- Cash generation following $28,742 (in thousands) of net cash provided by operating activities in the fiscal first quarter.
- The effect of business optimization, organizational restructure and executive severance costs, and costs related to the Downey, California center closure.
Balance sheet and cash flow
- Cash and cash equivalents were $119,253 (in thousands) as of September 30, 2026, compared with $97,891 (in thousands) as of June 30, 2026.
- Short-term investments were $43,740 (in thousands) as of September 30, 2026, compared with $43,435 (in thousands) as of June 30, 2026.
- The Company reported $61.4 million in debt, representing debt under its senior secured term loan, revolving credit facility and finance lease obligations.
- Net cash provided by operating activities was $28,742 (in thousands), compared with $3,924 (in thousands).
- Net cash used in investing activities was $(3,425) (in thousands), including purchases of property and equipment of $(2,988) (in thousands).
- Net cash used in financing activities was $(3,956) (in thousands).
Analysis
InnovAge began fiscal 2027 with $264,757 (in thousands) of total revenues, compared with $236,105 (in thousands) in the fiscal first quarter of 2026. The Company characterized the increase as approximately 12.1%. Census rose to approximately 8,420 participants from 7,890 participants, while member months rose to approximately 25,070 from 23,500. Capitation revenue was $264,690 (in thousands), comprising nearly all reported revenue.
Profitability increased materially. Income Before Income Taxes was $20,037 (in thousands), compared with $7,916 (in thousands), an approximately 153.1% increase. Its percentage of revenue was 7.6%, up 4.2 percentage points from 3.4%. Net Income was $20,878 (in thousands), compared with $7,669 (in thousands), and Net Income margin was 7.9%, up 4.6 percentage points. Net Income Attributable to InnovAge Holding Corp. was $19,553 (in thousands), or $0.14 per basic and diluted share, compared with $8,019 (in thousands), or $0.06 per share.
Non-GAAP operating measures also strengthened. Center-level Contribution Margin was $63,587 (in thousands), up 23.8% from $51,356 (in thousands), and its margin reached 24.0% from 21.8%. Adjusted EBITDA was $31,251 (in thousands), compared with $17,642 (in thousands), while Adjusted EBITDA margin increased to 11.8% from 7.5%. Corporate, general and administrative expense declined to $29,149 (in thousands) from $30,273 (in thousands), although the quarter included $1,707 (in thousands) of business optimization expense and $1,679 (in thousands) of offering expenses in the Adjusted EBITDA reconciliation.
Cash generation improved, with net cash provided by operating activities of $28,742 (in thousands), compared with $3,924 (in thousands). Cash and cash equivalents were $119,253 (in thousands) and short-term investments were $43,740 (in thousands) at September 30, 2026. InnovAge confirmed fiscal year 2027 guidance, including total revenues of $1,050 to $1,085 and Adjusted EBITDA of $105 to $115, both stated in dollars in millions. Management said that, effective in fiscal year 2027, prepared remarks will emphasize year-over-year performance rather than previously reported sequential-quarter comparisons.
Management, verbatim
We are pleased with our strong stat to fiscal 2027, as continued census growth along with disciplined clinical and operational execution drove strong financial performance.
Patrick Blair, Chief Executive Officer of InnovAge
Not in the filing
stated, not guessed- Gross margin was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- Guidance for gross margin, operating expenses and tax rate was not provided.
- Quarterly sequential comparisons were not reported in the financial-results discussion.
- Formal reportable-segment operating income was not reported.
- The previous outlook covered the full fiscal year 2027 only, and this release reports the first quarter, so there is nothing to compare for this period.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is the first public disclosure of InnovAge's Q1 performance and FY2027 outlook, released via SEC Form 8‑K and a GlobeNewswire press release.
Ticker impact
InnovAge Holding Corp. filed an 8‑K reporting Q1 2026 results and FY2027 guidance, revealing 12% revenue growth and double‑digit earnings improvement.
upward pressure as investors price in higher revenue and earnings outlook
Revenue and net income jumped significantly year‑over‑year and FY guidance exceeds prior expectations, suggesting better cash flow and growth prospects.
Market effects
Positive for the PACE/elder‑care sector, may boost peers with similar government‑payor exposure.
Limited to U.S. healthcare investors; no broader regional effect.
Modest, confined to U.S. small‑cap healthcare space.
Counterpoint
If guidance falls short of analyst consensus, the stock could face disappointment despite headline growth.
Key entities
- companyInnovAge Holding Corp.
NASDAQ‑listed provider of PACE senior‑care programs.
- executivePatrick Blair
CEO of InnovAge who commented on the results.



